News, Views & Reviews. Repurposing of Drugs for Dermatologic Applications: Five Key Medications

November 2014 | Volume 13 | Issue 11 | Features | 1413 | Copyright © November 2014


Brandon L. Adler BA and Adam J. Friedman MD

options outside limited FDA-approved regimens.1 It is important that practitioners and investigators continue to compile evidence supporting off-label applications in order to refine current practices and provide patients with the safest, most successful possible treatment choices.

Disclosures

The authors have no relevant disclosures to declare.
Brandon L. Adler BA and Adam J. Friedman MD
Department of Medicine (Division of Dermatology),
Albert Einstein College of Medicine, Bronx, NY

References

  1. Sugarman JH, Fleischer AB, Jr., Feldman SR. Off-label prescribing in the treatment of dermatologic disease. J Am Acad Dermatol. 2002;47(2):217-223.
  2. Li VW, Jaffe MP, Li WW, et al. Off-label dermatologic therapies. Usage, risks, and mechanisms. Arch Dermatol. 1998;134(11):1449-1454.
  3. Stafford RS. Regulating off-label drug use--rethinking the role of the FDA. N Engl J Med. 2008;358(14):1427-1429.
  4. Radley DC, Finkelstein SN, Stafford RS. Off-label prescribing among office-based physicians. Arch Intern Med. 2006;166(9):1021-1026.
  5. Fromm E, Wittmann J. Derivate des p-nitrophenols. Berichte Deutsch Chem Ges. 1908;41:2264-2273.
  6. Buttle G, Stephenson D, Smith S. The treatment of streptococcal infections in mice with 4:4’-diaminodiphenyl sulfone. The Lancet. 1937;1:1331-1334.
  7. Faget G, Pogge R, Johansen F, et al. The promin treatment of leprosy. Public Health Rep. 1943;58:1729-1741.
  8. Esteves J, Brandao F. Acerca da accao das sulfamidas e das sulfonas na doenca de Duhring. Trab Soc Portuguesa Dermatol Venereol. 1950;8:209-217.
  9. Coleman MD. Dapsone: modes of action, toxicity and possible strategies for increasing patient tolerance. Br J Dermatol. 1993;129(5):507-513.
  10. Zhu YI, Stiller MJ. Dapsone and sulfones in dermatology: overview and update. J Am Acad Dermatol. 2001;45(3):420-434.
  11. Bozeman PM, Learn DB, Thomas EL. Inhibition of the human leukocyte enzymes myeloperoxidase and eosinophil peroxidase by dapsone. Biochem Pharmacol. 1992;44(3):553-563.
  12. Wozel G, Blasum C. Dapsone in dermatology and beyond. Arch Dermatol Res. 2014;306(2):103-124.
  13. Wozel G. Dapson: Pharmakologie, Wirkmechanismus und klinischer Einsatz. Stuttgart, Germany: Thieme; 1996.
  14. Rogers 3rd R, Mehregan D. Dapsone therapy of cicatricial pemphigoid. Semin Dermatol. 1988;7(3):201-205.
  15. Grabbe J, Haas N, Möller A, et al. Erythema elevatum diutinum–evidence for disease-dependent leucocyte alterations and response to dapsone. Br J Dermatol. 2000;143(2):415-420.
  16. Yasuda H, Kobayashi H, Hashimoto T, et al. Subcorneal pustular dermatosis type of IgA pemphigus: demonstration of autoantibodies to desmocollin-1 and clinical review. Br J Dermatol. 2000;143(1):144-148.
  17. Thuong-Nguyen V, Kadunce DP, Hendrix JD, et al. Inhibition of neutrophil adherence to antibody by dapsone: a possible therapeutic mechanism of dapsone in the treatment of IgA dermatoses. J Invest Dermatol. 1993;100(4):349-355.
  18. Miyachi Y, Yoshioka A, Horio T, et al. Prurigo pigmentosa: a possible mechanism of action of sulfonamides. Dermatologica. 1986;172(2):82-88.
  19. Galaria NA, Junkins-Hopkins JM, Kligman D, et al. Neutrophilic dermatosis of the dorsal hands: pustular vasculitis revisited. J Am Acad Dermatol. 2000;43(5 Pt 1):870-874.
  20. Wolf R, Tuzun B, Tuzun Y. Dapsone: unapproved uses or indications. Clin Dermatol. 2000;18(1):37-53.
  21. Wozel V. Innovative use of dapsone. Dermatol Clin. 2010;28(3):599-610.
  22. Coleman MD. Dapsone toxicity: some current perspectives. General Pharmacology: The Vascular System. 1995;26(7):1461-1467.
  23. Fangmann P, Assion HJ, Juckel G, et al. Half a century of antidepressant drugs: on the clinical introduction of monoamine oxidase inhibitors, tricyclics, and tetracyclics. Part II: tricyclics and tetracyclics. J Clin Psychopharmacol. 2008;28(1):1-4.
  24. Gillman PK. Tricyclic antidepressant pharmacology and therapeutic drug interactions updated. Br J Pharmacol. 2007;151(6):737-748.
  25. Richelson E. Tricyclic antidepressants and histamine H1 receptors. Mayo Clin Proc. 1979;54(10):669-674.
  26. Tennyson H, Levine N. Neurotropic and psychotropic drugs in dermatology. Dermatol Clin. 2001;19(1):179-197, x.
  27. Picardi A, Abeni D, Melchi CF, et al. Psychiatric morbidity in dermatological outpatients: an issue to be recognized. Br J Dermatol. 2000;143(5):983-991.
  28. Koo J, Lebwohl A. Psychodermatology: The Mind and Skin Connection. Am Fam Physician. 2001;64(11).
  29. Wong JW, Koo JY. Psychopharmacological Therapies in Dermatology. Dermatol Online J. 2013;19(5).
  30. Doggrell SA, Brown L. The spironolactone renaissance. Expert Opin Investig Drugs. 2001;10(5):943-954.
  31. Steelman S, Brooks J, Morgan E, et al. Anti-androgenic activity of spironolactone. Steroids. 1969;14(4):449-450.
  32. Shaw JC. Spironolactone in dermatologic therapy. J Am Acad Dermatol. 1991;24(2 Pt 1):236-243.
  33. Rathnayake D, Sinclair R. Use of spironolactone in dermatology. Skinmed. 2009;8(6):328-332; quiz 333.
  34. Keleştimur F, Şahin Y. Comparison of Diane 35 and Diane 35 plus spironolactone in the treatment of hirsutism. Fertil Steril. 1998;69(1):66-69.
  35. Hoedemaker C, Van Egmond S, Sinclair R. Treatment of female pattern hair loss with a combination of spironolactone and minoxidil. Australas J Dermatol. 2007;48(1):43-45.
  36. Stephens C, Conover L, Hochstein F, et al. Terramycin. VIII. Structure of aureomycin and terramycin. J Am Chem Soc. 1952;74(19):4976-4977.
  37. Sapadin AN, Fleischmajer R. Tetracyclines: nonantibiotic properties and their clinical implications. J Am Acad Dermatol. 2006;54(2):258-265.
  38. Thong Y, Ferrante A. Inhibition of mitogen-induced human lymphocyte proliferative responses by tetracycline analogues. Clin Exp Immunol. 1979;35(3):443.
  39. Monk E, Shalita A, Siegel DM. Clinical applications of non-antimicrobial tetracyclines in dermatology. Pharmacol Res. 2011;63(2):130-145.
  40. Cunliffe W, Forster R, Greenwood N, et al. Tetracycline and acne vulgaris: a clinical and laboratory investigation. Br Med J. 1973;4(5888):332.
  41. Esterly NB, Koransky JS, Furey NL, et al. Neutrophil chemotaxis in patients with acne receiving oral tetracycline therapy. Arch Dermatol. 1984;120(10):1308-1313.
  42. Wilkin JK. Rosacea: pathophysiology and treatment. Arch Dermatol. 1994;130(3):359.
  43. Bachelez H, Senet P, Cadranel J, et al. The use of tetracyclines for the treatment of sarcoidosis. Arch Dermatol. 2001;137(1):69-73.
  44. Dezube BJ, Krown SE, Lee JY, et al. Randomized phase II trial of matrix metalloproteinase inhibitor COL-3 in AIDS-related Kaposi’s sarcoma: an AIDS Malignancy Consortium Study. J Clin Oncol. 2006;24(9):1389-1394.
  45. Lesher JL, McConnell RC. Antimicrobial Drugs. In: Bolognia JL, Jorizzo JL, Schaffer JV, eds. Dermatology. Third ed. Philadelphia, PA: Elsevier Saunders; 2012:1391-1421.
  46. Melchert M, List A. The thalidomide saga. Int J Biochem Cell Biol. 2007;39(7-8):1489-1499.
  47. Wu J, Huang D, Pang K, et al. Thalidomide: dermatological indications, mechanisms of action and side-effects. Br J Dermatol. 2005;153(2):254-273.
  48. Mascaro J, Lecha M, Torras H. Thalidomide in the treatment of recurrent, necrotic, and giant mucocutaneous aphthae and aphthosis. Arch Dermatol. 1979;115(5):636.
  49. Saylan T, Saltik I. Thalidomide in the treatment of Behcet’s syndrome. Arch Dermatol. 1982;118(8):536-536.
  50. Barba RJ, Franco GF. [Fixed lupus erythematosus (its treatment with thalidomide)]. Med Cutan Ibero Lat Am. 1976;5(4):279-285.
  51. Grosshans E, Illy G. Thalidomide therapy for inflammatory dermatoses. Int J Dermatol. 1984;23(9):598-602.
  52. Londoño F. Thalidomide in the treatment of actinic prurigo. Int J Dermatol. 1973;12(5):326-328.
  53. Gnassia A, Gnassia R, Bonvalet D, et al. Histiocytose X avec ‘granulome eosinophile vulvaire’: effet spectaculaire de la thalidomide. Ann Dermatol Venereol. 1987;114:1387-1389.
  54. Estines O, Revuz J, Wolkenstein P, et al. [Sarcoidosis: thalidomide treatment in ten patients]. Ann Dermatol Venereol. 2001;128(5):611-613.
  55. Cherouati K, Claudy A, Souteyrand P, et al. [Treatment by thalidomide of chronic multiforme erythema: its recurrent and continuous variants. A retrospective study of 26 patients]. Ann Dermatol Venereol. 1995;123(6-7):375-377.
  56. Vogelsang GB, Farmer ER, Hess AD, et al. Thalidomide for the treatment of chronic graft-versus-host disease. N Engl J Med. 1992;326(16):1055-1058.
  57. Moulin G, Bonnet F, Barrut D, et al. [Treatment of Jessner-Kanof disease with thalidomide]. Ann Dermatol Venereol. 1982;110(8):611-614.
  58. Silva S, Viana P, Lugon N, et al. Thalidomide for the treatment of uremic pruritus: a crossover randomized double-blind trial. Nephron. 1994;67(3):270-273.
  59. Wines NY, Cooper AJ, Wines MP. Thalidomide in dermatology. Australas J Dermatol. 2002;43(4):229-240.
  60. Nunley JR, Wolverton SE. Systemic Drugs. In: Bolognia JL, Jorizzo JL, Schaffer JV, eds. Dermatology. Third ed. Philadelphia, PA: Elsevier Saunders; 2012:2165-2181.
Close Menu